Insulin Resistance and Renal Function Tests Alterations in People Living With HIV on Antiretroviral Therapy at Shanahan University Teaching Hospital, Onitsha, Nigeria

Authors

  • ODO, V.C Department of Medical Laboratory Sciences, Tansian University, Orba Campus, Anambra State, Nigeria Author
  • ANYADIKE, N.N Department of Medical Laboratory Sciences, Tansian University, Orba Campus, Anambra State, Nigeria Author
  • IBOYI NATHANIEL ONUCHE Dept. of Biology and Forensic Science, Admiralty University of Nigeria, Ibusa, Delta State, Nigeria Author

DOI:

https://doi.org/10.68050/JAMS.2026.569

Keywords:

HIV; antiretroviral therapy; insulin resistance; HOMA-IR; QUICKI; fasting insulin; renal function; creatinine; urea; Nigeria.

Abstract

The increasing survival of people living with HIV (PLWH) following widespread access to antiretroviral therapy (ART) has shifted clinical attention toward long-term metabolic and renal comorbidities. Insulin resistance and impaired renal function may occur through a complex interaction involving persistent immune activation, HIV-associated metabolic abnormalities, traditional cardiometabolic risk factors and adverse effects of selected antiretroviral agents. This study assessed insulin resistance and renal function test alterations among people living with HIV receiving ART at Shanahan University Teaching Hospital, Onitsha, Nigeria. A comparative study involving 120 participants divided equally into three groups of 40 was undertaken: HIV-negative controls, HIV-positive participants not receiving ART, and HIV-positive participants receiving ART. Glycaemic and insulin-resistance indices included fasting glucose, glycated haemoglobin (HbA1c), fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI). Renal indices included serum urea, creatinine, sodium, potassium, bicarbonate and chloride. Group means were compared using analysis of variance (ANOVA), with statistical significance set at p < 0.05. Marked differences in metabolic indices were observed across the three groups. Fasting glucose was 4.59 ± 0.29 mmol/L in controls, 5.61 ± 0.55 mmol/L in HIV-positive participants not on ART and 5.27 ± 0.42 mmol/L in those receiving ART. Corresponding fasting insulin concentrations were 6.21 ± 1.05, 13.33 ± 5.86 and 8.68 ± 2.40 μIU/mL, while HOMA-IR values were 1.27 ± 0.29, 3.49 ± 1.82 and 2.22 ± 1.23, respectively. QUICKI demonstrated the opposite pattern, with values of 0.37 ± 0.01, 0.34 ± 0.04 and 0.39 ± 0.06, respectively. Renal assessment showed increased serum creatinine among both HIV groups compared with controls: 82.70 ± 11.33 μmol/L in controls, 92.58 ± 10.89 μmol/L in HIV-positive participants not on ART and 90.18 ± 10.42 μmol/L in participants on ART. Urea was highest among participants not on ART (5.72 ± 1.02 mmol/L) and declined to 4.81 ± 0.81 mmol/L among those receiving ART, compared with 4.59 ± 0.56 mmol/L in controls. The findings demonstrate significant metabolic and biochemical differences between HIV-positive and HIV-negative participants, particularly in insulin sensitivity and serum creatinine. HIV-positive participants not receiving ART demonstrated the greatest degree of insulin resistance, whereas ART-treated participants showed partial improvement in insulin-resistance indices but retained evidence of altered renal biochemical parameters. The findings support integration of metabolic and renal surveillance into routine HIV care in Nigeria.

18 3

References

1. American Diabetes Association Professional Practice Committee. (2024). 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement 1), S20–S42.

2. American Diabetes Association Professional Practice Committee. (2025). 11. Chronic kidney disease and risk management: Standards of Care in Diabetes—2025. Diabetes Care, 48(Supplement 1), S239–S251.

3. Chadwick, D. R., Barker, F., Smith, C., Perditer, O., Hardy, Y., Owusu, D., Villa, G., Sarfo, F. S., Geretti, A.-M., & Phillips, R. (2024). Prevalence and predictors of long-term progression of chronic kidney disease in people with HIV in Ghana from 2003–2018. BMC Nephrology, 25, 241.

4. David, E. A., Olayanju, O. A., Sanusi, K. O., Mabadeje, O. I., Mshelia, P. P., Orabueze, I., Kunle-Ope, C. N., Ezenwosu, I., Mamuda, K., Atinge, S., Adeniran, A. G., Akiode, S. O., Okeke, O. P., Abodunrin, O. R., Akinsolu, F. T., & Sobande, O. O. (2025). Determinants of metabolic syndrome in people living with human immunodeficiency virus in Africa: A systematic review and meta-analysis. Frontiers in Reproductive Health, 7, 1689731.

5. Diba, G., Arkew, M., Belete, R., Asmerom, H., & Tesfa, T. (2026). Prevalence of chronic kidney disease and associated factors among adult HIV patients in Africa: A systematic review and meta-analysis. SAGE Open Medicine, 14, 20503121261419300.

6. Dzudzor, B., Essel, S., Musah, L., Agyekum, J. A., & Yeboah, K. (2023). Metabolic syndrome and combination antiretroviral therapy in HIV patients in periurban hospital in Ghana: A case-control study. AIDS Research and Treatment, 2023, 1566001

7. Ebasone, P. V., Dzudie, A., Peer, N., Aseneh, J., Mbende, R. E., & Kengne, A.-P. (2026). Prevalence of cardiometabolic diseases among ART-naïve people with HIV: A global systematic review and meta-analysis. HIV Medicine.

8. Høgh, J., Hove-Skovsgaard, M., Gelpi, M., Jensen, A. M. R., Gerstoft, J., Benfield, T., Storgaard, H., & Nielsen, S. D. (2022). Insulin resistance in people living with HIV is associated with exposure to thymidine analogues and/or didanosine and prior immunodeficiency. BMC Infectious Diseases, 22, 503.

9. Hsu, R., Brunet, L., Fusco, J. S., Mounzer, K., Vannappagari, V., Henegar, C. E., Van Wyk, J., Curtis, L., Lo, J., & Fusco, G. P. (2021). Incident type 2 diabetes mellitus after initiation of common HIV antiretroviral drugs. AIDS, 35(1), 81–90..

10. Jumare, J., Dakum, P., Sam-Agudu, N., Memiah, P., Nowak, R., Bada, F., Oguama, U., Odonye, G., Adebiyi, R., Cairo, C., Kwaghe, V., Adebamowo, C., Abimiku, A., & Charurat, M. (2023). Prevalence and characteristics of metabolic syndrome and its components among adults living with and without HIV in Nigeria: A single-center study. BMC Endocrine Disorders, 23, 160.

11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314.

12. Lartey, M., Kenu, E., Ganu, V., Addo, S. A., Agyabeng, K., Bandoh, D., Abdulai, M., Tsekpetse, P., & Torpey, K. (2024). Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: An observational longitudinal study. Journal of Health, Population and Nutrition, 43, 199

13. Levin, A., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., Lamb, E., Lin, P., Madero, M., McIntyre, N., Morrow, K., Roberts, G., Sabanayagam, D., Schaeffner, E., Shlipak, M., ... Stevens, P. E. (2024). Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: Known knowns and known unknowns. Kidney International, 105(4), 684–701.

14. Li, X., Li, K., Li, Y., Zhao, Y., Huang, Y., Luo, J., Jiang, L., Li, S., Jing, J., & Ning, C. (2026). Diabetes risk in HIV infection and antiretroviral therapy: A systematic review and meta-analysis of prospective cohort evidence. HIV Medicine, 27(8), 1225–1240.

15. Lucas, A., & Wyatt, C. M. (2022). HIV at 40: Kidney disease in HIV treatment, prevention, and cure. Kidney International, 102(4), 740–749.

16. Mahanani, M. R., Chit, M., Mohr, S., Cama i Gibernau, E., Hetjens, S., Winkler, V., Steffen, H.-M., & Neuhann, F. (2026). Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta-analysis. HIV Medicine.

17. Markos, Z., Lonsako, D. T., Tekletsadik, Y. A., Aligaz, E. M., Godebo, A. S., Mamo, T., Hassen, A. A., Tafesse, D., Lorato, S. S., & Lema, D. A. (2026). Magnitude and factors associated with diabetes mellitus among people living with HIV/AIDS in Eastern Africa: Evidence from Ethiopia, Kenya, Uganda and Tanzania. A systematic review and meta-analysis. Endocrine, 91(1), 244

18. Mulindwa, F., Kamal, H., Castelnuovo, B., Byonanebye, D. M., Schwarz, J.-M., Bollinger, R., & Brusselaers, N. (2023). Association between integrase strand transfer inhibitor use with insulin resistance and incident diabetes mellitus in persons living with HIV: A systematic review and meta-analysis. BMJ Open Diabetes Research & Care, 11(1.

19. Nwatarali, C. G., Mamven, M. H., Adejumo, O. A., & Nwankwo, E. A. (2023). Kidney dysfunction in HIV-positive patients on HAART in a Nigerian tertiary hospital: A comparative study. Nigerian Medical Journal, 63(6), 455–460.

20. Olabisi, O. A., & Freedman, B. I. (2021). APOL1-associated kidney disease in northern Nigerians with treated HIV infection. Kidney International, 100(1), 19–21. doi:10.1016/j.kint.2021.04.023.

21. Ojong, E., Iya, B., Djeufouata, J., Ndeh, F., Nsonwu, A., Njongang, V., Etukudo, M., Usoro, C., & Ekpo, J. (2022). Metabolic syndrome and its components among HIV/AIDS patients on antiretroviral therapy and ART-naïve patients at the University of Calabar Teaching Hospital, Calabar, Nigeria. African Health Sciences, 22(1), 410–417..

22. Peer, N., Nguyen, K. A., Hill, J., Sumner, A. E., Cikomola, J. C., Nachega, J. B., & Kengne, A.-P. (2023). Prevalence and influences of diabetes and prediabetes among adults living with HIV in Africa: A systematic review and meta-analysis. Journal of the International AIDS Society, 26(3), e26059.

23. Roberts, N. L. S., Fadhil, S., Willkens, M., Ruselu, G., Desderius, B., Kanenda, S., Rudovick, L., Kavishe, B. B., Koenig, S. P., Tummalapalli, S. L., Lee, M. H., & Peck, R. N. (2025). HIV and CKD in the tenofovir era: A prospective parallel-group cohort study from Tanzania. Kidney Medicine, 7(1), 100937.

24. Torpey, K., Ganu, V., Kenu, E., Addo, S. A., Agyabeng, K., Odikro, M. A., Adu-Gyamfi, R., Mohammed, A. G., & Lartey, M. (2025). Metabolic syndrome among a Ghanaian cohort living with HIV initiated on dolutegravir in a real-world setting: A prospective study. BMJ Open, 15(5), e097340.

25. Wearne, N., & Davidson, B. (2024). HIV-associated kidney disease: The changing spectrum and treatment priorities. Current Opinion in Nephrology and Hypertension, 33(6), 603–612.

26. Wearne, N., Davidson, B., Blockman, M., Jones, J., Ross, I. L., & Dave, J. A. (2023). Management of type 2 diabetes mellitus and kidney failure in people with HIV-infection in Africa: Current status and a call to action. HIV/AIDS—Research and Palliative Care, 15, 519–535. doi:10.2147/HIV.S396949.

27. Zhao, F., & Lu, H. (2024). Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review. Bioscience Trends, 18(2), 141–152.

Downloads

Published

2026-09-30

How to Cite

Insulin Resistance and Renal Function Tests Alterations in People Living With HIV on Antiretroviral Therapy at Shanahan University Teaching Hospital, Onitsha, Nigeria. (2026). Journal of Advanced Multidisciplinary Studies (JAMS), Page 868-880. https://doi.org/10.68050/JAMS.2026.569

Similar Articles

21-30 of 177

You may also start an advanced similarity search for this article.